Apogee Therapeutics, Inc. Capital Expenditures
Apogee Therapeutics, Inc. (APGE) reported Capital Expenditures of $5.15 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-05-11
- Apogee Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $62.00K.
- Apogee Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Apogee Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $768.00K, a 1405.88% increase year-over-year.
- Apogee Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $4.32M, a 1129.91% increase year-over-year.
- Apogee Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $5.15M, a 346.79% increase from fiscal 2024.
- Apogee Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $1.15M, a 589.82% increase from fiscal 2023.
- Apogee Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $167.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $62.00K derived: sum of 2 quarters · filed 2026-03-02 | $830.00K derived: sum of 3 quarters · filed 2026-03-02 | $5.15M 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $768.00K derived: sum of 2 quarters · filed 2025-11-10 | $5.08M 10-Q · filed 2025-11-10 | $5.08M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-06-30 | $768.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $5.08M 10-Q · filed 2025-08-11 | $5.08M derived: sum of 3 quarters · filed 2026-05-11 | $5.83M derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-03-31 | $4.32M 10-Q · filed 2026-05-11 | $4.32M derived: sum of 2 quarters · filed 2026-05-11 | $5.07M derived: sum of 3 quarters · filed 2026-05-11 | $5.12M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $750.00K derived: sum of 2 quarters · filed 2026-03-02 | $801.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.15M 10-K · filed 2026-03-02 |
| 2024-09-30 | $751.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $802.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.15M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $402.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $351.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $167.00K 10-K · filed 2026-03-02 |